Trial Profile

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tivozanib (Primary) ; Sorafenib
Indications Renal cell carcinoma
Focus Registrational; Therapeutic Use
Acronyms TIVO-3
Sponsors AVEO Oncology

Most Recent Events

16 Sep 2024 According to a AVEO Oncology media release, data from this trial presented at the 2024 European Society of Medical Oncology (ESMO) congress
16 Sep 2024 Results published in the AVEO Oncology Media Release
17 Mar 2023 Results of subgroup analysis assessing the clinical efficacy of tivozanib in patients with advanced metastatic renal cell carcinoma previously treated with axitinib, published in the Oncologist.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com